Ligand Pharmaceuticals (Ligand Pharmaceuticals) COGS-to-Revenue : 0.06 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Ligand Pharmaceuticals COGS-to-Revenue?

Ligand Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $1.6 Mil. Its Revenue for the three months ended in Dec. 2023 was $28.1 Mil.

Ligand Pharmaceuticals's COGS to Revenue for the three months ended in Dec. 2023 was 0.06.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ligand Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 was 94.16%.

Ligand Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Ligand Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals COGS-to-Revenue Chart

Ligand Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.09

0.19

0.26

0.27

0.08

Ligand Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.43	0.08	0.06	0.11	0.06

Ligand Pharmaceuticals COGS-to-Revenue Calculation

Ligand Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	10.512	/	131.314
	=	0.08

Ligand Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.641	/	28.101
	=	0.06

Ligand Pharmaceuticals (NAS:LGND) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ligand Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1.641 / 28.101
	=	94.16 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Ligand Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

LGDN:Germany

Address

3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121

Website

https://www.ligand.com

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Executives

Martine Zimmermann	director	C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon	officer: CHIEF LEGAL OFFICER &	C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza	officer: Chief Financial Officer	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich	director	10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba	director	DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins	officer: CEO & President	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas	director	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr	officer: EVP and COO	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina	director	81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran	director	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman	officer: Asso. Gen. Counsel, Secretary	11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel	director	11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282